(Q47834206)

6 February 2018

title

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice (English)

1 reference

6 February 2018

0 references

8

Virander S Chauhan

1 reference

6 February 2018

author name string

Yengkhom Sangeeta Devi

1

1 reference

6 February 2018

Paushali Mukherjee

2

1 reference

6 February 2018

Syed Shams Yazdani

3

1 reference

6 February 2018

Ahmad Rushdi Shakri

4

1 reference

6 February 2018

Suman Mazumdar

5

1 reference

6 February 2018

Sunita Pandey

6

1 reference

6 February 2018

Chetan E Chitnis

7

1 reference

6 February 2018

language of work or name

English

0 references

publication date

21 May 2007

1 reference

6 February 2018

number of pages

9

1 reference

inferred from page(s)

published in

Vaccine

1 reference

6 February 2018

volume

25

1 reference

6 February 2018

issue

28

1 reference

6 February 2018

page(s)

5166-5174

1 reference

6 February 2018

Evolutionary and historical aspects of the burden of malaria

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Plasmodium vivax: Merozoites, invasion of reticulocytes and considerations for malaria vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

High dose of primaquine in primaquine resistant vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Plasmodium vivax malaria vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

A reticulocyte-binding protein complex of plasmodium vivax merozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Plasmodium vivax MSP-1 peptides have high specific binding activity to human reticulocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

What is the function of MSP-I on the malaria merozoite?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Both epidermal growth factor-like domains of the merozoite surface protein-1 from Plasmodium yoelii are required for protection from malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Immunization against blood-stage rodent malaria using purified parasite antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

The Resistance Factor to Plasmodium vivax in Blacks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Cloning of the Plasmodium vivax Duffy receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Erythrocyte Receptors for (Plasmodium Knowlesi) Malaria: Duffy Blood Group Determinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

A high cell density fermentation strategy to produce recombinant malarial antigen in E. coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

7 January 2021

Tissue sulfhydryl groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

The neglected burden of Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

7 January 2021

Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

7 January 2021

Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

7 January 2021

A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.080

7 January 2021

10.1016/J.VACCINE.2007.04.080

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

17544179

1 reference

6 February 2018